Cantargia announces pre-clinical results showing positive effects of CAN04 combined with approved cancer therapies
Cantargia AB today announces pre-clinical results from a study combining the antibody CAN04 (nidanilimab) and chemotherapy. In in vivo based models of cancer, CAN04 was safely combined with the tested chemotherapies. The strongest result was obtained by combining CAN04 with cisplatin, demonstrating both a significantly improved therapeutic effect as well as a clear CAN04-related reduction of cisplatin side effects.Cantargia develops antibody-based pharmaceuticals against the interleukin 1 receptor accessory protein (IL1RAP). The lead drug candidate CAN04 is in a phase I/IIa clinical trial (